title: Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma?
authors: Malik E
authors: ME
authors: Juweid
authors: Brian
authors: B
authors: Smith
authors: Emmanuel
authors: E
authors: Itti
authors: Michel
authors: M
authors: Meignan
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007167:Immunotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging* / Q000628:therapy; D049268:Positron-Emission Tomography / Q000379:methods / Q000592:standards*; D019275:Radiopharmaceuticals
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18